{"id":514305,"date":"2021-07-19T07:03:10","date_gmt":"2021-07-19T11:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/"},"modified":"2021-07-19T07:03:10","modified_gmt":"2021-07-19T11:03:10","slug":"eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/","title":{"rendered":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021"},"content":{"rendered":"

<\/p>\n

Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021<\/b><\/p>\n

Management team also provides investor updates at the Ladenburg Thalmann Healthcare Conference and \u201cLunch with LifeSci Featuring Eyenovia\u201d events<\/i><\/p>\n

NEW YORK & LAGUNA HILLS, Calif.–(BUSINESS WIRE<\/a>)–Eyenovia, Inc.<\/a> (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP\u2122) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, \u201cPresbyopia: Everybody gets it… but can it be fixed?\u201d\n<\/p>\n

\nThe company recently successfully completed its Phase 3 VISION-1 study of MicroLine<\/a>, its proprietary pilocarpine formulation delivered via its touchless, microdose Optejet\u00ae dispenser, for on demand improvement in near vision in patients with presbyopia.\n<\/p>\n

\nIn addition, management delivered two business and clinical update presentations; replay links to both can be found below.\n<\/p>\n

Details of the Eyecelerator panel are below:<\/b><\/p>\n\n\n\n\n\n
\n

Panel:<\/b><\/p>\n<\/td>\n

\n\n

\nPresbyopia: Everybody gets it\u2026but can it be fixed?\n<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n\n

\nMandalay Bay South Convention Center, Las Vegas
\n
Oceanside Ballroom CD, Level 2\n<\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n\n

\nThursday, July 22, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

Time:<\/b><\/p>\n<\/td>\n

\n\n

\n2:15pm PT (5:15pm ET)\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Business and Clinical Update Presentations:<\/b><\/p>\n

\nEyenovia\u2019s management team recently hosted two comprehensive business and clinical update presentations:\n<\/p>\n

\nA replay of the \u201cLunch with LifeSci Featuring Eyenovia\u201d event, which took place on July 13, can be found here<\/a>.\n<\/p>\n

\nA replay of the Ladenburg Thalmann presentation, which took place on July 14, can be found here<\/a>.\n<\/p>\n

About Eyecelerator <\/b><\/p>\n

\nEyecelerator is a partnership between the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology to connect entrepreneurs, investors, businesses and ophthalmologists to accelerate ophthalmic innovation and improve patient outcomes. For more information, visit https:\/\/eyecelerator.com<\/a>.\n<\/p>\n

About ASCRS <\/b><\/p>\n

\nASCRS is an international educational society with ophthalmic surgeons at every career stage. Its mission is to empower anterior segment surgeons to improve the vision, outcomes and quality of life for their patients through innovative approaches to education, advocacy and philanthropy. For more information, visit ascrs.org.<\/a><\/p>\n

\n\u200bAbout Eyenovia, Inc.<\/b><\/p>\n

\nEyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company\u2019s lead product candidate, Mydcombi\u2122 (tropicamide\/phenylephrine fixed combination) for use in diagnostic eye exams, has an FDA PDUFA date of October 28, 2021. For more information, visit www.eyenovia.com<\/a>.\n<\/p>\n

\nThe Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com\/events-and-presentations<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210719005100\/en\/<\/a><\/span><\/p>\n

Eyenovia Contact:
\n<\/b>
Eyenovia, Inc.
\n
John Gandolfo
\n
Chief Financial Officer
\n
jgandolfo@eyenovia.com
\n<\/a><\/p>\n

Eyenovia Investor Contact:
\n<\/b>
Eric Ribner
\n
LifeSci Advisors, LLC
\n
eric@lifesciadvisors.com
\n<\/a>
(646) 751-4363<\/p>\n

Eyenovia Media Contact:
\n<\/b>
Sam Choinski
\n
Pazanga Health Communications
\n
schoinski@pazangahealth.com
\n<\/a>
(603) 489-5964\n<\/p>\n

KEYWORDS:<\/b> United States North America California New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Medical Devices Health Finance Pharmaceutical Optical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 Management team also provides investor updates at the Ladenburg Thalmann Healthcare Conference and \u201cLunch with LifeSci Featuring Eyenovia\u201d events NEW YORK & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP\u2122) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, \u201cPresbyopia: Everybody gets it… but can it be fixed?\u201d The company recently successfully completed its Phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its touchless, microdose Optejet\u00ae dispenser, for on demand improvement in near vision in … <\/p>\n

Continue reading “Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-514305","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 Management team also provides investor updates at the Ladenburg Thalmann Healthcare Conference and \u201cLunch with LifeSci Featuring Eyenovia\u201d events NEW YORK & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP\u2122) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, \u201cPresbyopia: Everybody gets it… but can it be fixed?\u201d The company recently successfully completed its Phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its touchless, microdose Optejet\u00ae dispenser, for on demand improvement in near vision in … Continue reading "Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T11:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021\",\"datePublished\":\"2021-07-19T11:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/\"},\"wordCount\":489,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/\",\"name\":\"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-19T11:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/","og_locale":"en_US","og_type":"article","og_title":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 - Market Newsdesk","og_description":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 Management team also provides investor updates at the Ladenburg Thalmann Healthcare Conference and \u201cLunch with LifeSci Featuring Eyenovia\u201d events NEW YORK & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP\u2122) therapeutics, today announced that Eyenovia will be featured at the Company Showcase on July 22 at the Eyecelerator@ASCRS and will participate in a panel discussion, entitled, \u201cPresbyopia: Everybody gets it… but can it be fixed?\u201d The company recently successfully completed its Phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its touchless, microdose Optejet\u00ae dispenser, for on demand improvement in near vision in … Continue reading \"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-19T11:03:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021","datePublished":"2021-07-19T11:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/"},"wordCount":489,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/","name":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-19T11:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210719005100r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyenovia-to-participate-in-a-presbyopia-panel-discussion-at-eyecelerator-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=514305"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514305\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=514305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=514305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=514305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}